15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on July 23. Sangamo expects to be the first company to...
22:49 , Jul 23, 2018 |  BC Extra  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on Monday. Sangamo expects to be the first company to bring...
15:40 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

Reviving NK cells

Researchers from the University of Science and Technology of China have identified a key role for TIGIT in NK cell exhaustion that suggests immunotherapies targeting TIGIT may be useful against cancers that have failed to...
18:18 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Immutep reports ORR data for eftilagimod plus Keytruda in Phase I for melanoma

Immutep Ltd. (ASX:IMM; NASDAQ:IMMP) said eftilagimod alpha (IMP321) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to a best overall response rate (ORR) of 61% in 18 previously treated patients with...
22:06 , Jun 14, 2018 |  BC Innovations  |  Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together, data...
01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
22:41 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal damage Patient sample, cell culture and mouse studies suggest MIF or its receptor CD74 could help treat ischemia/reperfusion-associated acute kidney injury (AKI). In serum samples from 60 cardiac bypass surgery patients who experienced surgery-related...
14:12 , May 18, 2018 |  BC Week In Review  |  Company News

Medigene, bluebird expand TCR deal

Medigene AG (Xetra:MDG1) and bluebird bio Inc. (NASDAQ:BLUE) are adding two new targets and additional milestones to a 2016 deal to research and develop T cell receptor immunotherapies to treat cancer. Medigene will receive an additional...
19:28 , May 14, 2018 |  BC Extra  |  Company News

Medigene, bluebird expand TCR partnership

Medigene AG (Xetra:MDG1) and bluebird bio Inc. (NASDAQ:BLUE) are adding two new targets and additional milestones to a 2016 deal to research and develop T cell receptor immunotherapies to treat cancer. Medigene rose €1.35 to...